These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 17139760)

  • 61. Should you go generic?
    Carmichael M
    Newsweek; 2008 Oct; 152(15):78. PubMed ID: 18975394
    [No Abstract]   [Full Text] [Related]  

  • 62. What a pain.
    Drug Ther Bull; 2015 May; 53(5):49. PubMed ID: 25953642
    [No Abstract]   [Full Text] [Related]  

  • 63. A switch in time saves more than nine. Two popular statins, Pravachol and Zocor, go generic this summer, paving the way for significant savings.
    Harv Heart Lett; 2006 May; 16(9):1-2. PubMed ID: 16688877
    [No Abstract]   [Full Text] [Related]  

  • 64. Cutting drug costs. Brand names go generic.
    Mayo Clin Health Lett; 2008 Dec; 26(12):7. PubMed ID: 19174846
    [No Abstract]   [Full Text] [Related]  

  • 65. Antibiotics--an investment worth making?
    Christoffersen RE
    Nat Biotechnol; 2006 Dec; 24(12):1512-4. PubMed ID: 17160052
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Copycats gear up to dog biotech brands.
    Wadman M
    Nature; 2006 Oct; 443(7111):496-7. PubMed ID: 17024060
    [No Abstract]   [Full Text] [Related]  

  • 67. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs.
    Perucca E; Albani F; Capovilla G; Bernardina BD; Michelucci R; Zaccara G
    Epilepsia; 2006; 47 Suppl 5():16-20. PubMed ID: 17239100
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
    Kong Y
    Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
    [TBL] [Abstract][Full Text] [Related]  

  • 70. What's the problem with generic antiepileptic drugs?: a call to action.
    Berg MJ
    Neurology; 2007 Apr; 68(16):1245-6. PubMed ID: 17438211
    [No Abstract]   [Full Text] [Related]  

  • 71. Payers, consumers benefit as patents expire.
    Manag Care; 2006 Sep; 15(9):72. PubMed ID: 17036942
    [No Abstract]   [Full Text] [Related]  

  • 72. [Return the compass--but to whom?].
    Onfelt C
    Tidsskr Nor Laegeforen; 2006 Feb; 126(5):636; author reply 636. PubMed ID: 16505885
    [No Abstract]   [Full Text] [Related]  

  • 73. Where have all the antibiotic patents gone?
    Katz ML; Mueller LV; Polyakov M; Weinstock SF
    Nat Biotechnol; 2006 Dec; 24(12):1529-31. PubMed ID: 17160057
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Generics in psychiatry--do they have the same therapeutic equivalence as the original?].
    Kasper S; Lentner S
    Neuropsychiatr; 2008; 22(4):221-2. PubMed ID: 19080992
    [No Abstract]   [Full Text] [Related]  

  • 75. [Medical problems and risks of switching drugs according to legal requirements of drug discount contracts in Germany].
    Pruszydlo MG; Quinzler R; Kaltschmidt J; Haefeli WE
    Dtsch Med Wochenschr; 2008 Jul; 133(27):1423-8. PubMed ID: 18592450
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharma industry in India.
    Sundaram VM
    Drug News Perspect; 2008; 21(1):59-63. PubMed ID: 18301810
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Fractured European market undermines biosimilar launches.
    Moran N
    Nat Biotechnol; 2008 Jan; 26(1):5-6. PubMed ID: 18183000
    [No Abstract]   [Full Text] [Related]  

  • 78. Bilski blundering biotech.
    Simmons WJ
    Nat Biotechnol; 2009 Mar; 27(3):245-8. PubMed ID: 19270670
    [No Abstract]   [Full Text] [Related]  

  • 79. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Blockbusters for cheap? The difficulties surrounding generic biologics.
    Josephson SA; Johnston SC; Hauser SL
    Ann Neurol; 2013 Sep; 74(3):A7-8. PubMed ID: 24115256
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.